Skip to main content

FDA Approvals

Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors

Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma

Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer

Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia

Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-versus-Host Disease

Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease

Jakafi a New Treatment Option for Chronic Graft-versus-Host Disease

Page 10 of 53
Results 91 - 100 of 524